AstraZeneca Pharma India Limited – Q1 FY26 Results Summary
Announcement Date: August 14, 2025

• Revenue: Rs 5,263.1 mn, up 36% YoY (Q1 FY26 vs Q1 FY25) and 10% QoQ.
• Profitability:
  • Profit before exceptional items & tax: Rs 750.6 mn (+77% YoY)
  • Profit after tax: Rs 558.3 mn vs loss of Rs (117.9) mn in Q1 FY25
  • EPS: Rs 22.33 vs (4.72) in Q1 FY25
• Margins: Not explicitly stated; implied improvement given profit growth.
• Exceptional Items: Rs (3.6) mn in Q1 FY26 related to manufacturing site closure and restructuring; prior periods included higher exceptional costs.
• Balance Sheet Highlights: Manufacturing site operations ceased; plant and machinery fully depreciated; decommissioning underway. No new capex or acquisitions reported.
• Segment Performance: Single Healthcare segment; therapy area revenues: Oncology Rs 3,702.7 mn (up from Rs 2,394.2 mn), Biopharmaceuticals Rs 1,183.2 mn (slight decline), Rare Disease Rs 4.2 mn.
• Management Commentary: CFO attributes strong performance to innovation and disciplined execution; MD highlights consistent growth and commitment to patient outcomes.
• Strategic Initiatives: Shift towards becoming a specialist-focused biopharmaceutical organization; multiple CDSCO approvals for new indications in Oncology and Rare Diseases during the quarter.
• Auditor’s Opinion: Unqualified Limited Review Report with no concerns.
• Outlook: Not explicitly provided in this filing.

This summary reflects AstraZeneca Pharma India Limited’s improved financial results and ongoing strategic transformation in Q1 FY26.